 Home > Active Ingredient News > Drugs Articles > CStone Pharmaceuticals shares are officially included in Southbound Trading

CStone Pharmaceuticals shares are officially included in Southbound Trading

 Last Update: 2021-09-12
 Source: Internet
 Author: User

Tags

samumed stock

charlottes webb stock

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

(Suzhou, China, September 6, 2021) CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616), a leading biopharmaceutical company focused on research, development and commercialization of innovative tumor immunotherapies and precision therapeutic drugs, announced today that the company The stock was officially included in the Southbound Stock Connect list and became effective on the same day
.

This means that domestic investors who meet the relevant qualifications can directly trade the company's stock through the Southbound Stock Connect channel

Dr.
Jiang Ningjun, Chairman and CEO of CStone Pharmaceuticals said:

"The inclusion of CStone Pharmaceuticals in Southbound Stock Connect fully demonstrates the recognition of the company's strength and value by the capital market.
We also look forward to further expanding the investor base in the Mainland through Southbound Connect
.

CStone Pharmaceuticals has been committed to satisfying the eagerness of cancer patients in China and around the world.

In the first half of 2021, CStone Pharmaceuticals successfully launched two first-of-its-kind precision tumor treatment drugs, Pugeta® (Platinib) and Taijihua® (Avatinib), and achieved excellent sales performance
.

In addition, CStone Pharmaceuticals has also submitted four new drug listing applications (NDAs), and two first-in-class/potentially best-in-class products, Avonib and Shuglizumab, will be approved soon, highlighting the company’s strong R&D capabilities and Commercialization capabilities

About CStone Pharmaceuticals

CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616) is a biopharmaceutical company that focuses on research, development and commercialization of innovative tumor immunotherapy and precision treatment drugs to meet the ardent medical needs of cancer patients in China and around the world
.

Established at the end of 2015, CStone Pharmaceuticals has assembled a world-class management team with extensive experience in new drug development, clinical research and commercial operations

For more information, please visit
.

Forward-looking statement

The forward-looking statements made in this article only relate to events or information as of the date when the statement is made in this article
.

Except as required by law, we have no obligation to update or publicly revise any forward-looking statements and unexpected events after the date of forward-looking statements, regardless of whether there are new data, future events or other circumstances

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.